Late Breaking News
Follow Us
2012 Compendium
Department of Defense (DoD)
Army Panel Finds No More Changes in PTSD Diagnoses Than Other Conditions
WASHINGTON - A new Army report suggests that doctors made changes to PTSD diagnoses during the Medical Evaluation Board (MEB) process at similar rates to other behavioral health diagnoses, “suggesting that PTSD is not handled differently than other diagnoses.”
Autograft Better in ACL Repair for Army Cadets
WEST POINT, NY - Young military cadets undergoing an allograft ACL reconstruction were significantly more likely to experience clinical failure requiring revision reconstruction than those who underwent autologous graft reconstruction, according to researchers from the U.S. Military Academy at West Point, NY.
High Rates of Injury Identified in Army MP Training
ABERDEEN PROVING GROUND, MD - A new study is the first to identify injury rates and identify specific factors increasing injury risk during military police (MP) training in the Army.
Greater Weight Gain Seen After Knee Replacement Surgery
RICHMOND, VA - While knee-replacement surgery often is sought so patients can return to a more active lifestyle, patients who undergo the procedure might be at greater risk of gaining weight than those who have not had the surgery.
TRICARE Faces Challenges in Getting Males to Complete Three-Shot HPV Vaccine Series
Immunization Now Covered for Men Up to Age 27
FALLS CHURCH, VA - In the year since TRICARE added coverage for the human papillomavirus (HPV) vaccine in all males up to age 27, the challenge has been both educating military personnel and their families about the need for the shots and assuring that the recommended three doses are received.
Stivarga Approved for Some Stromal Tumors After Use of First-Line Therapies
WAYNE, NJ - Tthe U.S. Food and Drug Administration (FDA) has approved Bayer's Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate, according to Bayer HealthCare and Onyx Pharmaceuticals, Inc.
Kadcyla Approved for Treatment of HER2-positive Metastatic Breast Cancers
SAN FRANCISCO - The FDA has approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.
Retired Air Force Urologist, General Officer Urges Doctors to Take Command
TEMPLE, TX - Retired Brig. Gen. James T. Turlington, MD, may no longer be an active duty general officer in the Air Force, but he’s still practicing medicine — and still making a difference.
Lawmakers Seek Continued TBI Funding to Benefit Veterans, Civilians
WASHINGTON - Lawmakers are calling for the reauthorization of legislation to help traumatic brain injury (TBI) patients and their families access rehabilitation, long-term care and community support.
Controversy Continues Over Abridged Plans to Develop Joint VA, DoD EHR
WASHINGTON - The new plan to develop a joint DoD, VA iEHR is a "lower risk, lower cost path," agency officials told a congressional committee.
Most Popular Stories
- Many Healthcare Providers Lose VA Retention Bonuses
- Federal Medicine Organizational Meetings — Tarred with the Same Brush?
- Despite Formulary, High-Cost Diabetes Drug Use Varies Widely Across VA Facilities
- Report Says Administration Faces Hard Choices For Veterans Programs
- Physician Overcomes TBI to Return to Active-Duty Medicine
Education
Join Our E-Mail List


